RICFY:OTC-Recordati Industria Chimica e Farmaceutica S.p.A. (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 13

Change

0.00 (0.00)%

Market Cap

USD 9.85B

Volume

612.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

+5.77 (+3.79%)

USD 244.48B
RHHVF Roche Holding AG Participation

-4.74 (-1.66%)

USD 230.69B
RHHBY Roche Holding Ltd ADR

-0.17 (-0.48%)

USD 230.09B
RHHBF Roche Holding AG

+0.01 (+0.00%)

USD 228.39B
NVSEF Novartis AG

+0.51 (+0.48%)

USD 209.79B
SNYNF Sanofi

-0.10 (-0.11%)

USD 116.35B
GLAXF GSK plc

-0.18 (-0.86%)

USD 84.01B
DSKYF Daiichi Sankyo Company Limited

+2.02 (+6.02%)

USD 67.59B
DSNKY Daiichi Sankyo Co Ltd ADR

+0.65 (+1.90%)

USD 65.97B
CHGCY Chugai Pharmaceutical Co Ltd A..

+1.00 (+6.00%)

USD 54.01B

ETFs Containing RICFY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 9.85B 47% F 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.